U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07304128) titled 'A Study of PLB-002 in Advanced Solid Tumors' on Dec. 01.
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.
Study Start Date: Jan. 12, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: PLB-002
antibody drug conjugate (ADC)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Primelink BioTherapeitics(ShenZhen) Limited
Published by HT Digital Content Services with permission from Health Daily Digest....